Targeting eNOS in pancreatic cancer

Benjamin L. Lampson, S. Di Sean Kendall, Brooke B. Ancrile, Meghan M. Morrison, Michael J. Shealy, Katharine S. Barrientos, Matthew S. Crowe, David F. Kashatus, Rebekah R. White, Susan Gurley, Diana M. Cardona, Christopher M. Counter

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Mortality from pancreatic ductal adenocarcinoma cancer (PDAC) is among the highest of any cancer and frontline therapy has changed little in years. Activation of endothelial nitric oxide synthase (eNOS, NOS3, or NOS III) has been implicated recently in the pathogenesis of PDACs. In this study, we used genetically engineered mouse and human xenograft models to evaluate the consequences of targeting eNOS in PDACs. Genetic deficiency in eNOS limited the development of preinvasive pancreatic lesions and trended toward an extended lifespan in mice with advanced pancreatic cancer. These effects were also observed upon oral administration of the clinically evaluated NOS small molecule inhibitor NG-nitro-L-arginine methyl ester (L-NAME). Similarly, other transgenic models of oncogenic KRas-driven tumors responded to L-NAME treatment. Finally, these results were recapitulated in xenograft models of human pancreatic cancer, in which L-NAME was found to broadly inhibit tumorigenic growth. Taken together, our findings offer preclinical proof-of-principle to repurpose L-NAME for clinical investigations in treatment of PDACs and possibly other KRas-driven human cancers.

Original languageEnglish (US)
Pages (from-to)4472-4482
Number of pages11
JournalCancer Research
Volume72
Issue number17
DOIs
StatePublished - Sep 1 2012
Externally publishedYes

Fingerprint

NG-Nitroarginine Methyl Ester
Pancreatic Neoplasms
Heterografts
Neoplasms
Nitric Oxide Synthase Type III
Oral Administration
Adenocarcinoma
Therapeutics
Mortality
Growth

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Lampson, B. L., Kendall, S. D. S., Ancrile, B. B., Morrison, M. M., Shealy, M. J., Barrientos, K. S., ... Counter, C. M. (2012). Targeting eNOS in pancreatic cancer. Cancer Research, 72(17), 4472-4482. https://doi.org/10.1158/0008-5472.CAN-12-0057

Targeting eNOS in pancreatic cancer. / Lampson, Benjamin L.; Kendall, S. Di Sean; Ancrile, Brooke B.; Morrison, Meghan M.; Shealy, Michael J.; Barrientos, Katharine S.; Crowe, Matthew S.; Kashatus, David F.; White, Rebekah R.; Gurley, Susan; Cardona, Diana M.; Counter, Christopher M.

In: Cancer Research, Vol. 72, No. 17, 01.09.2012, p. 4472-4482.

Research output: Contribution to journalArticle

Lampson, BL, Kendall, SDS, Ancrile, BB, Morrison, MM, Shealy, MJ, Barrientos, KS, Crowe, MS, Kashatus, DF, White, RR, Gurley, S, Cardona, DM & Counter, CM 2012, 'Targeting eNOS in pancreatic cancer', Cancer Research, vol. 72, no. 17, pp. 4472-4482. https://doi.org/10.1158/0008-5472.CAN-12-0057
Lampson BL, Kendall SDS, Ancrile BB, Morrison MM, Shealy MJ, Barrientos KS et al. Targeting eNOS in pancreatic cancer. Cancer Research. 2012 Sep 1;72(17):4472-4482. https://doi.org/10.1158/0008-5472.CAN-12-0057
Lampson, Benjamin L. ; Kendall, S. Di Sean ; Ancrile, Brooke B. ; Morrison, Meghan M. ; Shealy, Michael J. ; Barrientos, Katharine S. ; Crowe, Matthew S. ; Kashatus, David F. ; White, Rebekah R. ; Gurley, Susan ; Cardona, Diana M. ; Counter, Christopher M. / Targeting eNOS in pancreatic cancer. In: Cancer Research. 2012 ; Vol. 72, No. 17. pp. 4472-4482.
@article{b27f361fb223453fb7832d066ca753f3,
title = "Targeting eNOS in pancreatic cancer",
abstract = "Mortality from pancreatic ductal adenocarcinoma cancer (PDAC) is among the highest of any cancer and frontline therapy has changed little in years. Activation of endothelial nitric oxide synthase (eNOS, NOS3, or NOS III) has been implicated recently in the pathogenesis of PDACs. In this study, we used genetically engineered mouse and human xenograft models to evaluate the consequences of targeting eNOS in PDACs. Genetic deficiency in eNOS limited the development of preinvasive pancreatic lesions and trended toward an extended lifespan in mice with advanced pancreatic cancer. These effects were also observed upon oral administration of the clinically evaluated NOS small molecule inhibitor NG-nitro-L-arginine methyl ester (L-NAME). Similarly, other transgenic models of oncogenic KRas-driven tumors responded to L-NAME treatment. Finally, these results were recapitulated in xenograft models of human pancreatic cancer, in which L-NAME was found to broadly inhibit tumorigenic growth. Taken together, our findings offer preclinical proof-of-principle to repurpose L-NAME for clinical investigations in treatment of PDACs and possibly other KRas-driven human cancers.",
author = "Lampson, {Benjamin L.} and Kendall, {S. Di Sean} and Ancrile, {Brooke B.} and Morrison, {Meghan M.} and Shealy, {Michael J.} and Barrientos, {Katharine S.} and Crowe, {Matthew S.} and Kashatus, {David F.} and White, {Rebekah R.} and Susan Gurley and Cardona, {Diana M.} and Counter, {Christopher M.}",
year = "2012",
month = "9",
day = "1",
doi = "10.1158/0008-5472.CAN-12-0057",
language = "English (US)",
volume = "72",
pages = "4472--4482",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - Targeting eNOS in pancreatic cancer

AU - Lampson, Benjamin L.

AU - Kendall, S. Di Sean

AU - Ancrile, Brooke B.

AU - Morrison, Meghan M.

AU - Shealy, Michael J.

AU - Barrientos, Katharine S.

AU - Crowe, Matthew S.

AU - Kashatus, David F.

AU - White, Rebekah R.

AU - Gurley, Susan

AU - Cardona, Diana M.

AU - Counter, Christopher M.

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Mortality from pancreatic ductal adenocarcinoma cancer (PDAC) is among the highest of any cancer and frontline therapy has changed little in years. Activation of endothelial nitric oxide synthase (eNOS, NOS3, or NOS III) has been implicated recently in the pathogenesis of PDACs. In this study, we used genetically engineered mouse and human xenograft models to evaluate the consequences of targeting eNOS in PDACs. Genetic deficiency in eNOS limited the development of preinvasive pancreatic lesions and trended toward an extended lifespan in mice with advanced pancreatic cancer. These effects were also observed upon oral administration of the clinically evaluated NOS small molecule inhibitor NG-nitro-L-arginine methyl ester (L-NAME). Similarly, other transgenic models of oncogenic KRas-driven tumors responded to L-NAME treatment. Finally, these results were recapitulated in xenograft models of human pancreatic cancer, in which L-NAME was found to broadly inhibit tumorigenic growth. Taken together, our findings offer preclinical proof-of-principle to repurpose L-NAME for clinical investigations in treatment of PDACs and possibly other KRas-driven human cancers.

AB - Mortality from pancreatic ductal adenocarcinoma cancer (PDAC) is among the highest of any cancer and frontline therapy has changed little in years. Activation of endothelial nitric oxide synthase (eNOS, NOS3, or NOS III) has been implicated recently in the pathogenesis of PDACs. In this study, we used genetically engineered mouse and human xenograft models to evaluate the consequences of targeting eNOS in PDACs. Genetic deficiency in eNOS limited the development of preinvasive pancreatic lesions and trended toward an extended lifespan in mice with advanced pancreatic cancer. These effects were also observed upon oral administration of the clinically evaluated NOS small molecule inhibitor NG-nitro-L-arginine methyl ester (L-NAME). Similarly, other transgenic models of oncogenic KRas-driven tumors responded to L-NAME treatment. Finally, these results were recapitulated in xenograft models of human pancreatic cancer, in which L-NAME was found to broadly inhibit tumorigenic growth. Taken together, our findings offer preclinical proof-of-principle to repurpose L-NAME for clinical investigations in treatment of PDACs and possibly other KRas-driven human cancers.

UR - http://www.scopus.com/inward/record.url?scp=84865714641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865714641&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-12-0057

DO - 10.1158/0008-5472.CAN-12-0057

M3 - Article

C2 - 22738914

AN - SCOPUS:84865714641

VL - 72

SP - 4472

EP - 4482

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 17

ER -